Credit Suisse Ag Cel Sci Corp Transaction History

Credit Suisse Ag

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$3.09 - $5.23 $25,507 - $43,173	-8,255 Reduced 99.77%	19 $0
Q2 2022 Aug 12, 2022	SELL	$2.58 - $4.99 $48,614 - $94,026	-18,843 Reduced 69.49%	8,274 $38,000
Q1 2022 May 16, 2022	BUY	$3.93 - $7.7 $6,193 - $12,135	1,576 Added 6.17%	27,117 $106,000
Q4 2021 Feb 14, 2022	BUY	$7.1 - $12.82 $7,696 - $13,896	1,084 Added 4.43%	25,541 $182,000
Q3 2021 Nov 12, 2021	BUY	$7.64 - $12.49 $12,544 - $20,508	1,642 Added 7.2%	24,457 $270,000
Q2 2021 Aug 16, 2021	SELL	$8.68 - $27.49 $68,085 - $215,631	-7,844 Reduced 25.58%	22,815 $198,000
Q1 2021 May 14, 2021	SELL	$12.0 - $27.64 $471,708 - $1.09 Million	-39,309 Reduced 56.18%	30,659 $466,000
Q4 2020 Feb 12, 2021	SELL	$11.05 - $16.62 $48,133 - $72,396	-4,356 Reduced 5.86%	69,968 $815,000
Q3 2020 Nov 13, 2020	SELL	$11.69 - $14.54 $513,541 - $638,742	-43,930 Reduced 37.15%	74,324 $947,000
Q2 2020 Aug 12, 2020	BUY	$9.75 - $17.6 $1.15 Million - $2.08 Million	118,254 New	118,254 $1.77 Million
Q2 2019 Aug 14, 2019	SELL	$3.77 - $8.67 $205,216 - $471,942	-54,434 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$2.58 - $3.54 $140,439 - $192,696	54,434 New	54,434 $193,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.